Ding H - Search Results

1

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer.

Hu S, Ming H, He Q, Ding M, Ding H, Li C. Hu S, et al. Among authors: ding m, ding h. Front Oncol. 2024 Apr 8;14:1314301. doi: 10.3389/fonc.2024.1314301. eCollection 2024. Front Oncol. 2024. PMID: 38651148 Free PMC article.

2

Research Progress of Circular RNA in Gastrointestinal Tumors.

Fang N, Ding GW, Ding H, Li J, Liu C, Lv L, Shi YJ. Fang N, et al. Among authors: ding h, ding gw. Front Oncol. 2021 Apr 15;11:665246. doi: 10.3389/fonc.2021.665246. eCollection 2021. Front Oncol. 2021. PMID: 33937077 Free PMC article. Review.

3

MiR-96 induced non-small-cell lung cancer progression through competing endogenous RNA network and affecting EGFR signaling pathway.

Ding H, Chu M, Yue J, Huang H, Wang J, Zhu L. Ding H, et al. Iran J Basic Med Sci. 2019 Aug;22(8):908-914. doi: 10.22038/ijbms.2019.33654.8023. Iran J Basic Med Sci. 2019. PMID: 31579447 Free PMC article.

4

The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients.

Ding H, Chen Y, Zhao Y, Zhu L, Huang H, Liu C, Zhang F, Zhang C, Jin C. Ding H, et al. Cancer Biomark. 2022;35(1):119-125. doi: 10.3233/CBM-210281. Cancer Biomark. 2022. PMID: 35912729

5

Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer.

Ding H, Wen W, Ding Q, Zhao X. Ding H, et al. Among authors: ding q. Cancer Control. 2020 Jan-Dec;27(1):1073274820964783. doi: 10.1177/1073274820964783. Cancer Control. 2020. PMID: 33104396 Free PMC article. Retracted.

6

Neddylation pattern indicates tumor microenvironment characterization and predicts prognosis in lung adenocarcinoma.

Cui Y, Chen Z, Pan B, Chen T, Ding H, Li Q, Wan L, Luo G, Sun L, Ding C, Yang J, Tong X, Zhao J. Cui Y, et al. Among authors: ding h, ding c. Front Cell Dev Biol. 2022 Sep 13;10:979262. doi: 10.3389/fcell.2022.979262. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36176276 Free PMC article.

7

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report.

Zhao Y, Chen Y, Huang H, Li X, Shao L, Ding H. Zhao Y, et al. Among authors: ding h. Onco Targets Ther. 2021 May 7;14:3063-3067. doi: 10.2147/OTT.S300556. eCollection 2021. Onco Targets Ther. 2021. PMID: 33994798 Free PMC article.

8

Immune Landscape and Classification in Lung Adenocarcinoma Based on a Novel Cell Cycle Checkpoints Related Signature for Predicting Prognosis and Therapeutic Response.

Yang J, Chen Z, Gong Z, Li Q, Ding H, Cui Y, Tang L, Li S, Wan L, Li Y, Ju S, Ding C, Zhao J. Yang J, et al. Among authors: ding h, ding c. Front Genet. 2022 May 11;13:908104. doi: 10.3389/fgene.2022.908104. eCollection 2022. Front Genet. 2022. PMID: 35646074 Free PMC article.

9

Methylenetetrahydrofolate reductase tagging polymorphisms are associated with risk of non-small cell lung cancer in eastern Chinese Han population.

Ding H, Wang Y, Chen Y, Liu C, Qiu H, Kang M, Tang W. Ding H, et al. Oncotarget. 2017 Dec 4;8(66):110326-110336. doi: 10.18632/oncotarget.22887. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299150 Free PMC article.

10

Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.

Jiao XD, Ding LR, Zhang CT, Qin BD, Liu K, Jiang LP, Wang X, Lv LT, Ding H, Li DM, Yang H, Chen XQ, Zhu WY, Wu Y, Ling Y, He X, Liu J, Shao L, Wang HZ, Chen Y, Zheng JJ, Inui N, Zang YS. Jiao XD, et al. Among authors: ding lr, ding h. Transl Lung Cancer Res. 2021 Jul;10(7):3236-3250. doi: 10.21037/tlcr-21-543. Transl Lung Cancer Res. 2021. PMID: 34430361 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,808 results

Search Page